CAMP
Income statement / Annual
Last year (2025), CAMP4 Therapeutics Corp.'s total revenue was $3.50 M,
an increase of 436.50% from the previous year.
In 2025, CAMP4 Therapeutics Corp.'s net income was -$80.40 M.
See CAMP4 Therapeutics Corp.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
| Operating Revenue |
$3.50 M |
$652.00 K |
$350.00 K |
| Cost of Revenue |
$1.64 M
|
$0.00
|
$0.00
|
| Gross Profit |
$1.86 M
|
$652.00 K
|
$350.00 K
|
| Gross Profit Ratio |
0.53
|
1
|
1
|
| Research and Development Expenses |
$38.20 M
|
$38.82 M
|
$40.62 M
|
| General & Administrative Expenses |
$17.36 M
|
$14.92 M
|
$11.61 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$17.36 M
|
$14.92 M
|
$11.61 M
|
| Other Expenses |
-$1.64 M
|
$0.00
|
$0.00
|
| Operating Expenses |
$53.92 M
|
$53.74 M
|
$52.23 M
|
| Cost And Expenses |
$55.56 M
|
$53.74 M
|
$52.23 M
|
| Interest Income |
$2.17 M
|
$1.33 M
|
$2.81 M
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$1.64 M
|
$1.70 M
|
$1.68 M
|
| EBITDA |
-$50.42 M |
-$51.39 M |
-$50.20 M |
| EBITDA Ratio |
-14.41
|
-78.82
|
-143.43
|
| Operating Income Ratio |
-14.88
|
-81.42
|
-148.23
|
| Total Other Income/Expenses Net |
-$28.34 M
|
$1.30 M
|
$2.59 M
|
| Income Before Tax |
-$80.40 M
|
-$51.79 M
|
-$49.29 M
|
| Income Before Tax Ratio |
-22.99
|
-79.43
|
-140.83
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$80.40 M
|
-$51.79 M
|
-$49.29 M
|
| Net Income Ratio |
-22.99
|
-79.43
|
-140.83
|
| EPS |
-2.65 |
-2.66 |
-4.07 |
| EPS Diluted |
-2.65 |
-2.66 |
-4.07 |
| Weighted Average Shares Out |
$30.38 M
|
$19.51 M
|
$12.12 M
|
| Weighted Average Shares Out Diluted |
$30.38 M
|
$19.51 M
|
$12.12 M
|
| Link |
|
|
|
